Therapeutic interventions, in particular for neovascular age-related macular degeneration (AMD) offer a better degree of value than any other treatment right across the field of healthcare.
Opthea discontinues COAST and ShORe sozinibercept combination therapy trials
Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration
Higher Molar Dose and Its Translation into Clinical Practice
EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)
A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression
New study investigates ocular involvement in multiple myeloma
Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate
Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology
This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain
International study illuminates economic burden of late-stage age-related macular degeneration
Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US